Innovative Bispecific Nanobody Targeting IL12RB1 and IL12RB2 for Cancer Immunotherapy
VHH-P315 is a humanized nanobody program designed to target interleukin 12 receptor subunit beta 1 (IL12RB1) and interleukin 12 receptor subunit beta 2 (IL12RB2). The molecule is currently in the Biological Testing stage and offers strong therapeutic potential for cancer treatment. Leveraging highly selective single-domain antibodies, VHH-P315 aims to modulate critical immune pathways central to tumorigenesis. By engaging both IL12RB1 and IL12RB2 with high specificity, this agent represents an advanced modality with the promise of improved efficacy and reduced off-target effects compared to conventional biologics.
| Candidate | VHH-P315 |
| Target | interleukin 12 receptor subunit beta 1 (IL12RB1) interleukin 12 receptor subunit beta 2 (IL12RB2) |
| Modality | humanized bispecific VHH |
| Indication | Cancer |
Licensing Opportunity
VHH-P315 is currently available for out-licensing and collaborative development opportunities. Interested parties are invited to contact us for further information and partnership discussions to advance this innovative cancer immunotherapy.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P315 |
Modality
VHH-P315 is engineered as a heterodimeric agonistic bispecific antibody comprising single-domain nanobodies against IL12RB1 and IL12RB2. These VHH domains, derived from llamas and fused to an Fc region with rationally designed mutations, are produced using knob-and-hole technology and expressed in human embryonic kidney cells. The nanobody structure offers significant advantages such as smaller molecular size, enhanced tissue penetration, high stability, and reduced immunogenicity. These attributes enable effective localization to tumor microenvironments and interaction with immune targets that may be inaccessible to conventional antibodies, making VHH-P315 particularly advantageous for cancer therapy.
Target
IL12RB1 and IL12RB2 are integral components of the interleukin-12 receptor complex, serving as critical mediators in immune cell signaling. Both IL12RB1 and IL12RB2 are primarily expressed on subsets of lymphoid cells, such as T cells and natural killer cells, where they transduce signals essential for antitumor immune responses. Aberrant signaling through the IL12RB1 and IL12RB2 axis has been implicated in impaired immune surveillance in cancer. Targeting IL12RB1 and IL12RB2 offers a scientifically validated approach for enhancing immune activity against tumors. The strategic dual targeting by VHH-P315 harnesses the therapeutic promise of modulating IL12RB1 and IL12RB2 simultaneously, which may amplify antitumor immunity and offers a significant differentiation point for cancer immunotherapy development.
Mechanism of Action
VHH-P315 operates via dual agonistic engagement of the IL12RB1 and IL12RB2 subunits. By binding to these receptor components, VHH-P315 is designed to mimic and enhance endogenous interleukin-12 pathway activation, promoting the proliferation and cytotoxic activity of immune effectors such as T cells and NK cells within the tumor microenvironment. This targeted immune modulation aims to restore or amplify antitumor responses. Furthermore, the nanobody platform underlying VHH-P315 supports broad scalability, including the generation of antibody-drug conjugates or multispecific formats adapted for various oncologic and immune applications, significantly expanding its therapeutic relevance.
Cancer
Cancer remains one of the most significant global health burdens, with millions of new cases diagnosed annually across diverse populations. Despite advances in surgery, chemotherapy, radiation, immunotherapy, and targeted therapies, cancer continues to be a leading cause of morbidity and mortality worldwide. Standard care often faces challenges such as toxicity, drug resistance, limited specificity, and lack of durable responses. Current unmet clinical needs include therapies that can selectively enhance antitumor immunity while minimizing adverse effects. VHH-P315, by specifically targeting key immune activators IL12RB1 and IL12RB2, has the potential to offer a next-generation cancer immunotherapy. Its nanobody-based bispecific format is uniquely suited to modulating immune networks more precisely, addressing critical gaps left by conventional treatments and aiming to achieve improved outcomes in patients with difficult-to-treat tumors.